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Abstract: A meta-analysis of the association of iron overload with gestational diabetes mellitus
(GDM) may inform the health debate. We performed a meta-analysis investigating the association of
iron biomarkers and dietary iron exposure with GDM. We identified 33 eligible studies (N = 44,110)
published in 2001–2017. The standardized mean differences (SMD) in women who had GDM
compared to pregnant women without were 0.25 µg/dL (95% CI: 0.001–0.50) for iron, 1.54 ng/mL
(0.56–2.53) for ferritin, 1.05% (0.02 to 2.08) for transferrin saturation, and 0.81 g/dL (0.40–1.22)
for hemoglobin. Adjusted odds ratio for GDM were 1.58 (95% CI: 1.20–2.08) for ferritin, 1.30 (1.01–1.67)
for hemoglobin, and 1.48 (1.29–1.69) for dietary heme intake. We did not find any differences in TIBC
or transferrin concentration in women with and without GDM. We also did not find any association of
increased transferrin receptor or increased intake of total dietary iron, non-heme iron or supplemental
iron, with increased odds ratios for GDM. Considerable heterogeneity was present among the studies
(0–99%), but no evidence of publication bias. Accumulating evidence suggests that circulating and
dietary iron biomarkers among pregnant women are associated with GDM, but the results should be
interpreted with caution due to the high heterogeneity of analyses. Randomized trials investigating
the benefits of iron reduction in women at high risk for GDM are warranted.
Keywords: iron; ferritin; transferrin; gestational diabetes; pregnancy
1. Introduction
Body iron is tightly regulated and dependent on nutritional needs and availability [1].
Adequate iron is critical for β-cell function and glucose homeostasis but excess iron beyond the
need increases systemic oxidative stress [2]. Iron deficiency is common among pregnant women and
remains a global public health concern. The World Health Organization (WHO) recommends intake of
30–60 mg of elemental iron during pregnancy to prevent maternal iron deficiency anemia and to ensure
adequate fetal iron stores [1]. However, the health policy about the amount of iron supplementation
during pregnancy varies between countries.
It is evident that pregnant women have an increased demand for iron due to physiological expansion
of blood volume, needs of the fetus, and placental growth. Gestational diabetes mellitus (GDM) is associated
with risks for the mom and the fetus. O’Sullivan et al. originally recommended the first screening and
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diagnostic criteria in the 1960s [3]. Since then, there has been debate about screening and diagnostic criteria
for GDM. As such, various GDM diagnostic criteria have been adopted around the world by governing
agencies, and the criteria have been modified over the years [3,4]. Collectively, this results in variable
prevalence rates of GDM throughout the world. GDM is the most common metabolic disorder of pregnancy,
and increasing incidence rates of GDM are thought to reflect the global rise in the incidence of type 2
diabetes mellitus (T2DM) related to energy intake in excess of energy expenditure [5]. Therefore, strategies
addressing effective prevention, proper diagnosis and treatment are warranted. Fetal complications include
obstetric complications related to macrosomia, neonatal hypoglycemia, perinatal mortality, congenital
malformations, hyperbilirubinemia, polycythemia, hypocalcemia and respiratory distress syndrome [6].
The offspring are also at higher risk for glucose intolerance, diabetes and obesity in later years [6].
Maternal complications in women who develop GDM include hypertension, preeclampsia, cesarean
delivery and increased risk of developing diabetes after pregnancy [5,6].
It has been debated whether excess endogenous and exogenous (supplemental) iron is associated with
GDM, but so far the studies have been inconsistent and heterogeneous with respect to measurement of iron
exposure, ascertainment of GDM status, study design, and population demographics [7–38]. There have
been a few meta-analyses of observational studies published to date, but they are not comprehensive and
fail to provide conclusive evidence as to whether iron supplementation during pregnancy would pose
any risk to development of GDM. Two previous randomized clinical trials in pregnant women failed
to find any significant difference in the incidence of GDM in the iron supplement and placebo groups
but these studies suffered from limitations in trial design, compliance, and ascertainment of exposure
and outcome [19,39]. Most recently, Zhang et al. published a qualitative systematic review that critically
examined the association between dietary iron intake, iron status and gestational diabetes, but the study
did not provide quantitative estimates across the studies. Therefore, the aim of this study was to perform
a quantitative, meta-analysis of the association of dietary iron intake, iron supplementation, and circulating
iron biomarkers with GDM to inform the health debate.
2. Methods
2.1. Study Strategy
The study was conducted in accordance to Meta-analysis of Observational Studies in
Epidemiology (MOOSE) recommendations.
A systematic search of studies published before 27 November 2017 was conducted utilizing
a PubMed Search. The search was designed to capture records for articles describing the effect of iron
intake and serum biomarkers of iron and GDM: (“iron” [MeSH Terms] OR “iron” [All Fields]) AND
(“diabetes, gestational” [MeSH Terms] OR (“diabetes” [All Fields] AND “gestational” [All Fields])
OR “gestational diabetes” [All Fields] OR (“gestational” [All Fields] AND “diabetes” [All Fields])).
Additional articles were captured by references and citations found in the original search and from the
PubMed option “Similar Articles.”
2.2. Exposure
Exposure was defined as circulatory or dietary biomarkers of iron: hemoglobin (g/dL), ferritin
(ng/mL), total iron binding capacity (TIBC) (µg/dL), transferrin (mg/dL), transferrin saturation (%),
and transferrin receptor (mg/L). Dietary iron biomarkers included: total dietary iron with supplements,
dietary iron without supplements, non-heme iron, heme iron, and supplemental iron.
2.3. Outcomes
A diagnosis of gestational diabetes status was based either on oral glucose tolerance test (OGTT),
medical record, and/or self-report. More specifically, the OGTT diagnosis cutoff values utilized depend
on which criteria were used by the study (i.e., WHO, ADA, etc.). Specific criteria for each study are
specified in Table 1.
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Table 1. Characteristics of studies included in the meta-analyses.


























Marí-Sanchis et al. 2017 Spain Cohort 172 3298 Self Report 28.7 X X X
Behboudi-Gandevani et al. 2013 Iran Cohort 72 1033 OGTT 27.6 X X X X NR
Bowers et al. 2011 US Cohort 867 13,475 Self Report 31.4 X X X X
Chen et al. 2006 US Cohort 45 1456 OGTT 22.1 X X X Immunoradiometric
Darling et al. 2016 US Cohort 316 7229 Self Report NR X X
Helin et al. 2012 Finland Cohort 72 399 MedicalRecord/OGTT 29.3 X
Khambalia et al. 2015 Australia Cohort 129 3776 MedicalRecord NR X X X ELISA
Qiu et al. 2011 US Cohort 158 3158 MedicalRecord 32.7 X X
Rawal et al. 2017 US Case-Control 107 321 MedicalRecord 30.4 X X X Immunoturbidimetric
Soheilykhah et al. 2017 Iran Cohort 300 1358 OGTT 20.3–31.4 X X X X ELISA
Soubasi et al. 2010 Greece Cohort 6 63 MedicalRecord 24–37 X ELISA
Tarim et al. 2004 Turkey Cohort 20 253 OGTT 21.8–32.3 X X NR
Zein et al. 2015 Lebanon Cohort 16 104 OGTT 20–33 X X X Chemiluminescence
Chan et al. 2009 China RandomizedControl Trial 116 1164 OGTT 31.1–31.5 X
Afkhami-Ardekani et al. 2009 Iran Case-Control 34 68 OGTT NR X X X X X Immunoradiometric
Al Saleh et al. 2004 Kuwait Case-Control 15 30 Not Reported 23.1 X
Al Saleh et al. 2007 Kuwait Case-Control 10 21 Not Reported 28.0–33.7 X
Amiri et al. 2013 Iran Case-Control 100 200 OGTT 19.6–31.0 X X X Immunoradiometric
Derbent et al. 2013 Turkey Case-Control 30 102 OGTT 23.9–37 X X X Electrochemiluminescence
Gungor et al. 2007 Turkey Case-Control 56 112 OGTT 21.1–33.9 X MEIA
Javadian et al. 2014 Iran Case-Control 52 102 OGTT 22.3–37.8 X X Immunoradiometric
Kaygusuz et al. 2013 Turkey Case-Control 30 58 OGTT 28.7–32.8 X X X
Ozyer et al. 2014 Turkey Case-Control 35 105 OGTT 26.8–34.1 X
Sharifi et al. 2010 Iran Case-Control 64 128 OGTT 25.1–34.9 X X Immunoradiometric
Wang et al. 2002 China Cross-sectional 46 136 OGTT NR X
Akhlaghi et al. 2012 Iran Case-Control 30 60 OGTT 25–30 X
Pan et al. 2013 China Cross-sectional 243 713 OGTT 29.5 X
Lao et al. 2001 China Cross-sectional 97 291 OGTT 34.9–37.4 X X X X MEIA
Lao et al. 2002 China Cross-sectional 94 730 OGTT 29.7 X
Tan et al. 2011 Malaysia Cohort 182 1538 OGTT 24.6–36.9 X
Bowers et al. 2016 Denmark Case-Control 350 699 OGTT 25.7–36.5 X X Immunoturbidimetric
Bo et al. 2009 Italy Case-Control 500 1000 OGTT 28.3–41 X
Palma et al. 2008 Spain Case-Control 41 930 MedicalRecord 20–25 X
a: Mean or ranges provided. NR = Not reported; MEIA = Microparticle enzyme immunoassay.
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2.4. Inclusion Criteria
Studies were selected if they reported an association of iron biomarkers and GDM.
The following criteria were required for eligibility: (A) mean, standard deviation (SD), and N
of the continuous exposures in pregnant women with vs. without GDM, or (B) unadjusted and/or
adjusted odds ratio and 95% CI for the binary outcomes in pregnant women with vs. without GDM,
or (C) raw N for the 2 × 2 tables to calculate the odds ratio and 95% CI for the binary outcomes in
pregnant women with vs. without GDM.
2.5. Exclusion Criteria
We excluded abstracts, reviews, commentaries, studies with inadequate data, and studies in
languages other than English. “Inadequate data” is defined as data that were presented such that it
was impossible to extract or calculate the necessary values for inclusion into a meta-analysis.
2.6. Study Selection Process
One author (YK) first examined the study titles and abstracts. All studies identified as potentially
relevant to the topic were eligible for a full-text review. The study selection process is shown in Figure 1.
A list of selected studies can be found in Table 1. A total of 33 eligible studies were identified [7–38].
Figure 1. Selection of studies. Note: Australia, Europe, and USA were clustered due to the limited
number of studies in individual analyses.
2.7. Risk of Bias and Study Quality Assessment
The quality of each study was evaluated and scored using the nine-star Newcastle–Ottawa
Scale (NOS), a tool used for quality assessment of nonrandomized studies [40]. This was done
independently by two authors (YK & YW). Studies were evaluated based on selection, comparability,
exposure, and outcome, and scored with a maximum of nine points. Scores above five indicate
moderate to high study quality. The NOS for cohort and case-control studies was retrieved from:
http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf.
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2.8. Data Extraction
Two authors (YK & YW) extracted information from the selected studies. The following variables
were obtained from each study: author, size of study, year of publication, journal, name of study,
assessment of GDM, GDM diagnosis criteria, assay type, the number of people with outcome/no
outcome in exposed and non-exposed groups, odds ratio with 95% confidence interval (CI) or
standard error (SE), mean and SD for continuous variables for exposed and non-exposed groups,
and adjustment variables. Table 1 shows details of the selected studies and the data extracted from
each study.
2.9. Data Synthesis and Meta-Analysis
Analysis was performed using STATA statistical software version 13.1. We combined summary
estimates from all the studies in a meta-analysis.
We used the metan command to calculate random effects summary estimates in STATA. Comparing
dietary and serum iron status to GDM vs. no GDM, we calculated weighted mean differences (WMD)
and standardized mean differences (SMD) for continuous variables, and a pooled odds ratio for blood
levels of ferritin, transferrin receptor, hemoglobin, and dietary iron intake. We meta-analyzed the
unadjusted and adjusted data separately. If studies presented odds ratios parsed by tertiles or quartiles
of iron status, we calculated a within-study fixed effect odds ratio for binary GDM status (yes/no)
before we meta-analyzed the odds ratios across studies. Statistical heterogeneity was assessed by the
I2 statistic, which is a measure of between study variance, and the corresponding Cochran’s Q-statistic
p-value (p(het)). To investigate the validity and robustness of the meta-analysis of the mean differences
in iron, ferritin, and hemoglobin, for which we had the most studies, we explored heterogeneity in
sensitivity analyses by stratifying on study size, continent, and study design, and we performed
leave-one-out analyses. Publication bias was measured by Begg’s test and Egger’s test and by visually
assessing funnel plots.
3. Results
After removing duplicates, 33 unique articles were identified (Figure 1). We included 33 studies
in the meta-analysis on blood biomarkers of iron and dietary iron intake and its association with
gestational diabetes. The Newcastle–Ottawa qualitative assessment scale of bias revealed a score of
5–8 in case-control studies and 6–9 in cohort studies (Table S1). Fifteen studies were from the Middle
East, six from Europe, six from Asia, six from the USA, and one from Australia.
The studies were published from 2001 to 2017. In total, 44,110 pregnant women were included
(age range 19 to 41 years).
3.1. Serum Iron
The SMD and WMD of serum iron in women who had GDM compared to pregnant women
without were 0.25 µg/dL (95% CI: 0.001 to 0.50; I2 = 83.4%, p(het) = 3.10 × 10−9) and 11.31 µg/dL
(95% CI: 0.87 to 21.75 I2 = 87.5%, p(het) = 4.63 × 10−13), respectively (Figure 2, Figures S1 and S2).
3.2. Serum Ferritin
The SMD and WMD of serum ferritin in women who had GDM compared to pregnant women
without were 1.54 ng/mL (95% CI: 0.56 to 2.53; I2 = 99.4.0%, p(het) = 0) and 11.33 n/g/dL (95% CI: 6.68
to 15.97; I2 = 92.4%, p(het) = 1.39 × 10−25), respectively (Figures 2 and 3, and Figure S3). Increased ferritin
concentration was associated with GDM with an unadjusted odds ratio of 1.84 (95% CI: 1.51 to 2.23;
I2 = 37.1%, p(het) = 1.1 × 10−1) (Figure 2 and Figure S4) and an adjusted odds ratio of 1.58 (95% CI: 1.20
to 2.08; I2 = 0.0%, p(het) = 3.83 × 10−7) (Figure 4 and Figure S4).
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Figure 2. Blood and dietary iron biomarkers and gestational diabetes status (mean difference).
Figure 3. Ferritin concentration (ng/mL) differences in GDM—standardized mean differences.
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Figure 4. Adjusted association between ferritin concentration (ng/mL) and GDM—adjusted odds ratio.
3.3. Total Iron Binding Capacity
The SMD and WMD of total iron binding capacity (TIBC) in women who had GDM compared to
pregnant women without were −0.47 µg/mL (95% CI: −1.07 to 0.14; I2 = 93.4%, p(het) = 8.0 × 10−10)
and −28.14 µg/dL (95% CI: −63.86 to 7.57; I2 = 94.6%, p(het) = 1.39 × 10−25), respectively (Figure 2,
Figures S5 and S6).
3.4. Transferrin Saturation and Transferrin Receptor
The SMD and WMD of transferrin saturation in women who had GDM compared to pregnant
women without were 1.05% (95% CI: 0.02 to 2.08; I2 = 93.6%, p(het) = 1.73 × 10−7) and 8.30% (95% CI:
1.38 to 15.22; I2 = 90.4%, p(het) = 3.04 × 10−5), respectively (Figure 2, Figures S7 and S8).
Increased transferrin receptor concentrations were associated with GDM with an unadjusted
odds ratio of 1.32 (95% CI: 0.73 to 2.37; I2 = 99.8%, p(het) = 3.70 × 10−206) (Figure 5 and Figure S12)
and an adjusted odds ratio of 1.18 (95% CI: 0.86 to 1.62; I2 = 77.8%, p(het) = 1.11 × 10−2) (Figure 5,
Figures S9 and S10).
3.5. Hemoglobin
The SMD and WMD for hemoglobin levels in women who had GDM compared to pregnant
women without were 0.81 g/dL (95% CI: 0.40 to 1.22; I2 = 95.9%, p(het) = 3.69 × 10−38) and 0.44 g/dL
(95% CI: 0.15 to 0.74; I2 = 93.9%, p(het) = 2.33 × 10−24), respectively (Figures 2 and 6 and Figure S11).
Increased hemoglobin concentration was associated with GDM with an unadjusted odds ratio of 1.34
(95% CI: 1.19 to 1.50; I2 = 22.5%, p(het) = 2.71 × 10−1) (Figure 5 and Figure S12) and an adjusted odds
ratio of 1.30 (95% CI: 1.01 to 1.67; I2 = 51.0%, p(het) = 8.59 × 10−2) (Figure 5 and Figure S13).
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Figure 5. Differences in iron and gestational diabetes status (odds ratio).
Figure 6. Hemoglobin concentration (g/dL) differences in GDM—standardized mean difference.
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3.6. Dietary Iron Biomarkers
Total dietary iron, not including supplements, was not associated with GDM. The unadjusted
OR was 0.96 (95% CI: 0.85 to 1.10; I2 = 78.6%, p(het) = 9.28 × 10−3) (Figure 5 and Figure S14) and the
adjusted OR was 1.08 (95% CI: 0.80 to 1.44; I2 = 64.9%, p(het) = 3.58 × 10−2) (Figure 5 and Figure S15).
Dietary non-heme iron intake was not associated with GDM, with unadjusted OR of 0.80
(95% CI: 0.64 to 1.01; I2 = 81.8%, p(het) = 9.00 × 10−4) and adjusted OR of 0.84 (95% CI: 0.64 to 1.11;
I2 = 82.9%, p(het) = 5.50 × 10−4) (Figure 5, Figures S16 and S17).
Dietary heme iron intake was associated with GDM with an unadjusted OR of 1.53 (95% CI: 1.39
to 1.69; I2 = 0.0%, p(het) = 5.89 × 10−1) and adjusted OR of 1.48 (95% CI: 1.29 to 1.69; I2 = 33.9%,
p(het) = 2.09 × 10−1) (Figure 5, Figures S18 and S19).
Lastly, supplemental iron intake was not associated with GDM with an unadjusted OR of 1.20
(95% CI: 0.63 to 2.29; I2 = 93.7%, p(het) = 2.26 × 10−10) and adjusted OR of 1.09(95% CI: 0.73 to 1.63;
I2 = 82.7%, p(het) = 3.00 × 10−3) (Figure 5, Figures S20 and S21).
3.7. Heterogeneity and Publication Bias and Sensitivity Analysis
I2 heterogeneity varied from 0–99% but there was no publication bias present in the meta-analyses
(Figures 2 and 5). Stratifying the meta-analysis by study size, showed that larger studies had smaller
mean iron differences with narrow confidence intervals compared to smaller studies, but study
size did not influence the mean differences observed for ferritin and hemoglobin concentrations
(Figure S22). Stratifying the meta-analysis by geographical location revealed that studies from the
Middle East and Asia had the larger and more variable mean differences in iron and hemoglobin
levels (Figure S23), whereas mean differences in ferritin levels were higher among women of
European descent. Stratification by study design revealed a variable pattern and heterogeneity
(I2: 0–99%) amongst all studies for mean differences in iron, ferritin, and hemoglobin levels (Figure S24).
Lastly, no gross changes were found in iron, ferritin, and hemoglobin mean differences compared to
pooled sensitivity analysis conducted by leave-one-out analysis (Figures S25–S27).
4. Discussion
There has been growing literature suggesting that elevated iron concentration is associated
with the development of GDM. Understanding the relationship is imperative for designing future
randomized control trials to determine if pregnant women can benefit from early intervention.
We conducted a meta-analysis to determine if circulatory and dietary iron biomarkers are associated
with development of gestational diabetes. The findings from this meta-analysis suggested that mean
differences in circulating iron, ferritin, hemoglobin, and transferrin saturation were higher in women
with GDM compared to women without GDM, and increased ferritin, hemoglobin, and dietary heme
intake were associated with increased odds ratios for GDM. We did not find any meaningful differences
in TIBC and transferrin concentration in women with and without GDM. We also did not find any
association of increased transferrin receptor or increased intake of total dietary iron, non-heme iron or
supplemental iron, with increased odds ratio for GDM.
Ferritin concentrations were significantly and consistently associated with GDM across various
observational studies and other meta-analyses [41–45]. Of note, the relationship persisted across
different thresholds of high vs. low ferritin concentrations across different studies. It is also unclear
what threshold of iron elevation is associated with GDM. Ferritin is a marker utilized to assess
total body iron stores and it is also an acute phase reactant. The hormone hepcidin is the body’s
main regulator of systemic iron homeostasis, and it is secreted in response to iron loading and
inflammation [46]. Hepcidin has been associated with inflammatory states in humans [46,47]. The role
of hepcidin in pregnancy is poorly understood, and only two studies have examined the association
between GDM and hepcidin, both reporting increased hepcidin levels in GDM [15,24]. An increased
maternal serum hepcidin level in GDM could potentially be due to increased body iron stores
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or inflammation. Interestingly, Rawal et al. found that the relationship persisted after adjusting
for inflammation status (i.e., CRP levels). In a similar fashion, the association observed between ferritin
and GDM could be reflective of underlying inflammation and not iron status. Moreover, markers of
inflammation such as C-Reactive Protein (CRP) have also been associated with GDM [48]. To date,
only a handful of studies simultaneously assessed the CRP and ferritin with GDM [10,15,38,49,50].
Chen et al. showed that individuals with higher serum ferritin and CRP levels had the greatest risk
of GDM. This is consistent with Jiang et al. who has reported that high serum ferritin and CRP are
independent risk factors for Type 2 diabetes [51]. Collectively this suggests that inflammation may
mediate the development of GDM. However, in our analysis, other non-acute phase reactant markers
such as serum iron and hemoglobin were also associated with GDM.
No single circulating iron biomarker alone is reflective of true iron status. Clinical utility of
iron, ferritin, transferrin, transferrin saturation, soluble transferrin receptor are best when used
in combination. However, the majority of the included studies failed to measure all iron biomarkers.
Serum iron measures the amount of circulating iron; our pooled estimates suggested that there
was a positive and significant association between iron concentration and GDM. Animal model
studies have confirmed that glucose tolerance is decreased by iron supplementation and is increased
by iron depletion [52]. Whereas, transferrin, an iron transport protein, and transferrin saturation
is readily calculated to serve as a sensitive indicator of functional iron deficiency. Our pooled
estimates suggest that serum transferrin saturation is associated with GDM but not transferrin levels.
Soluble transferrin receptor is increased in iron deficiency but unlike ferritin is not confounded
by inflammation. All three studies published to date have found no significant association between
transferrin receptor and GDM risk [13,15,38]. It is possible that no association was seen since transferrin
receptor levels tend to rise only in the presence of a functional iron deficiency. Collectively, there were
a limited number of studies examining these associations and thus results should be evaluated critically.
Hemoglobin concentration is affected by hemodilution during pregnancy, and a decreased
concentration defines anemia; however, increased hemoglobin may be reflective of iron overload
but may also reflect heavy smoking, high altitude, or a bone marrow disorder. In the meta-analysis,
elevated hemoglobin concentration was associated with GDM.
Iron status of the body is regulated by dietary intake of the individual and also dependent on the
type of dietary iron (i.e., heme vs. non-heme). Heme and non-heme iron are derived from different food
sources and have different absorption mechanisms. Heme iron is derived largely from hemoglobin
and myoglobin in meat, poultry, and fish. On the contrary plants, dairy products, and supplements
are sources of non-heme iron. Dietary heme iron was positively and significantly associated with
GDM but total dietary iron and non-heme iron were not associated with GDM. This finding could be
attributable to the different absorption rates of heme and non-heme iron. Additionally the absorption
of heme iron is less influenced by other dietary factors compared to non-heme iron [53]. The negative
and non-significant association of non-heme with GDM could be serving as a proxy for other dietary
components that are reflective of a healthier diet but these findings are inconsistent. As such, fiber and
polyunsaturated fats have been reported to be inversely associated with GDM risk [54,55].
In support of our findings, a case-control study showed that the iron overload C282Y allele
frequency is higher in women with GDM than in healthy pregnant women, suggesting a genetic
susceptibility to the development of GDM [56]. Our group has also previously shown that iron
overload is associated with diabetes [57,58]. Higher levels of iron contribute to more reactive oxygen
species and oxidative stress, ultimately leading to damage of the pancreatic beta cells and impairing
insulin synthesis [59,60]. Reduction of the iron burden in type 2 diabetes animal models improve
beta cell function [2]. It is also plausible that iron excess might interfere with glucose metabolism and
trigger insulin resistance rather than impairing beta cells function. Animal models have shown that
iron overload results in insulin resistance and hepatic glucose production [61]. This maybe mediated
through the pancreatic beta-cells as it has a poor antioxidant capacity making them more susceptible
to oxidative damage ultimately leading to impaired insulin synthesis.
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Our meta-analysis is the most recent that comprehensively, critically, and quantitatively assesses
the association between serum iron biomarkers and dietary biomarkers with gestational diabetes.
Previous meta-analyses have either only qualitatively assessed the current data and/or are not
comprehensive [13,41,42,44,45]. However, our study has limitations that should to be considered.
Each meta-analysis had a variable number of studies included (3 to 12), which highlights the lack
and need for additional studies assessing the association between iron status and GDM. Majority of
the studies utilized either the ADA, WHO, or the Carpenter and Coustan OGTT diagnostic criteria.
Assessing the studies by continent, majority of the studies (15 in total) were from the Middle East,
six from Europe, six from Asia, five from the USA, and one from Australia. The GDM status
was different in different regions of the world, and amount of glucose for OGTT varied between
countries. These factors most likely contributed to the geographical heterogeneity that was observed
in the meta-analyses. There were also studies with self-reported GDM, which could introduce
misclassification bias and potentially affect the observed results. Additionally, the selection of
iron biomarkers to assess iron status varied among all the selected studies, which could potentially
introduce further bias in the observed results, and none of the studies used iron isotopes to measure
iron absorption. Moreover, the heterogeneous selection of assays across studies may introduce bias,
which may prevent us from observing a true association between iron status and GDM; however,
the use of the standardized mean difference largely reduces bias due to differences between assays.
Additionally, almost all of the studies were observational in nature thus residual confounding can
be expected. Recall bias may also be present in the questionnaire assessments of dietary iron intake.
The presence of random error also attenuates the associations observed in this study and favors the
null hypothesis.
The meta-analyses were based on observational studies, which are prone to confounding and
reverse causation. Two previous randomized clinical trials (RCT) have been conducted investigating
the effect of iron supplementation in healthy pregnant women and most with some degree of anemia,
but did not find any association [19,39]. These studies suffered from limitations in trial design,
compliance, and ascertainment of exposure and outcome. RCT studies would confirm findings seen
across the literature and help determine if reducing iron status would prevent diabetes and/or improve
glycemic control in patients with varying degrees of glucose intolerance; but to this date, no RCTs
have been conducted in women with first-time GDM or in women with a second pregnancy with
a previous history of GDM investigating the effects of iron supplementation on the mother and
the fetus. These studies are needed to identify if certain high-risk groups could benefit from iron
reduction or simply no iron supplement during pregnancy. Furthermore, concerns regarding iron
supplementation in women with adequate levels ought to be investigated.
In conclusion, the meta-analysis suggested that mean differences in circulating iron, ferritin,
hemoglobin, and transferrin saturation were higher in women with GDM compared to women
without GDM, and increased ferritin, hemoglobin, and dietary heme intake were associated with
increased odds ratios for GDM. Results should be interpreted with caution as the pooled estimates had
high heterogeneity, potentially due to geographical location, GDM assessment, and selection of iron
biomarkers and assays. The lack of association does not necessarily support the null hypothesis as
some analyses included only a few studies and thus have wider confidence intervals. There is a clear
need for larger and systematically conducted randomized controlled trials utilizing all the available
iron biomarkers to elucidate the potential benefit and risk of iron repletion among replete pregnant
women and in pregnant women at high risk of developing GDM.
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